Related Experiment Video
Updated: May 10, 2026
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy
Yunzhou Wu1, Shijun Yan, Zheng Lv
1College of Life Science, Northeast Agriculture University, Mucai Street 59, Xiangfang District, Harbin, China. deshanli@163.com.
Abstract:
Hepatocellular carcinoma remains one of the most common malignant tumors in the world. Newcastle disease virus (NDV) has been proved to be an efficient oncolytic agent. NDV tumor killing efficacy is not only dependening on the NDV strain but the type of tumor targeted. It is significant to discover more effective and safe oncolytic strains. We investigated the effectiveness of genetically engineered NDV Anhinga strain in hepatoma treatment. The modified virus containing an insertion of enhanced green fluorescent protein (EGFP), named NDV/Anh-EGFP. The antitumor efficacy of the recombinant virus on hepatoma was examined both in vivo and in vitro. NDV Anhinga strain, which could be classified as a lytic strain, is an effective oncolytic agent on hepatoma. There was no significant difference in the TCID50 and growth capability between the recombinant NDV and the parental. NDV/Anh-EGFP can obviously inhibit hepatocarcinoma development in vitro and in vivo. We demonstrate Anhinga strain could become a potent candidate for clinical carcinoma therapy especially for hepatocarcinoma.
Insights
Genetically engineered Newcastle disease virus (NDV) Anhinga strain effectively targets and inhibits hepatocarcinoma growth. This oncolytic virus shows promise for future liver cancer therapies.
Area of Science:
- Oncology
- Virology
- Biotechnology
Background:
- Hepatocellular carcinoma is a prevalent global malignancy.
- Newcastle disease virus (NDV) demonstrates oncolytic potential against tumors.
- Optimizing NDV strains for specific cancers like hepatoma is crucial.
Purpose of the Study:
- To evaluate the efficacy of a genetically engineered NDV Anhinga strain (NDV/Anh-EGFP) in treating hepatoma.
- To assess the antitumor effects of NDV/Anh-EGFP both in vitro and in vivo.
Main Methods:
- Genetic engineering of NDV Anhinga strain with enhanced green fluorescent protein (EGFP) insertion.
- In vitro and in vivo studies to examine the antitumor efficacy of the recombinant NDV/Anh-EGFP.
- Comparison of TCID50 and growth capability between recombinant and parental NDV strains.
Main Results:
- The recombinant NDV/Anh-EGFP maintained similar TCID50 and growth characteristics to the parental strain.
- NDV/Anh-EGFP demonstrated significant inhibition of hepatocarcinoma development in vitro.
- In vivo studies confirmed the potent inhibition of hepatocarcinoma growth by NDV/Anh-EGFP.
Conclusions:
- The NDV Anhinga strain is an effective oncolytic agent for hepatoma.
- Genetically engineered NDV/Anh-EGFP exhibits significant antitumor activity against hepatocarcinoma.
- The Anhinga strain is a promising candidate for clinical hepatocarcinoma therapy.
